HERON THERAPEUTICS, INC. /DE/ APIC, Share-based Payment Arrangement, Increase for Cost Recognition
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- HERON THERAPEUTICS, INC. /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.18M, a 13.62% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.98M, a 18.52% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.85M, a 4.78% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.80M, a 38.80% decline year-over-year.
- HERON THERAPEUTICS, INC. /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.34M, a 20.24% decline from fiscal 2024.
- HERON THERAPEUTICS, INC. /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $12.96M, a 60.55% decline from fiscal 2023.
- HERON THERAPEUTICS, INC. /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $32.85M, a 23.56% decline from fiscal 2022.
- HERON THERAPEUTICS, INC. /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $42.98M, a 8.26% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.18M 10-Q · filed 2026-08-10 | $6.15M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $2.98M 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $10.34M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $2.85M 10-Q · filed 2025-11-04 | $5.65M derived: sum of 2 quarters · filed 2026-08-10 | $8.16M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-06-30 | $2.80M 10-Q · filed 2026-08-10 | $5.31M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $2.51M 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $12.96M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $2.72M 10-Q · filed 2025-11-04 | $7.29M derived: sum of 2 quarters · filed 2025-11-04 | $10.67M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $4.57M 10-Q · filed 2025-11-04 | $7.95M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $3.38M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $32.85M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $6.68M 10-Q · filed 2024-11-12 | $20.58M derived: sum of 2 quarters · filed 2024-11-12 | $28.53M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $13.90M 10-Q · filed 2024-11-12 | $21.85M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $7.95M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $42.98M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $11.20M 10-Q · filed 2023-11-14 | $21.55M derived: sum of 2 quarters · filed 2023-11-14 | $32.47M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $10.35M 10-Q · filed 2023-11-14 | $21.27M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $10.91M 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $46.85M 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $11.24M 10-Q · filed 2022-11-08 | $22.48M derived: sum of 2 quarters · filed 2022-11-08 | $33.96M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $11.24M 10-Q · filed 2022-11-08 | $22.73M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $11.49M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $50.22M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $11.10M 10-Q · filed 2021-11-03 | $22.21M derived: sum of 2 quarters · filed 2021-11-03 | $34.18M derived: sum of 3 quarters · filed 2021-11-03 | |
| 2020-06-30 | $11.11M 10-Q · filed 2021-11-03 | $23.09M derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-03-31 | $11.97M 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $51.41M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $9.70M 10-Q · filed 2020-11-05 | $22.41M derived: sum of 2 quarters · filed 2020-11-05 | $40.31M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $12.71M 10-Q · filed 2020-11-05 | $30.61M derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $17.90M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $33.37M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $8.05M 10-Q · filed 2019-11-12 | $15.87M derived: sum of 2 quarters · filed 2019-11-12 | $23.57M derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $7.82M 10-Q · filed 2019-11-12 | $15.52M derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $7.70M 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $30.54M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $25.96M 10-K · filed 2019-02-22 | |||
| 2015-12-31 | $14.36M 10-K · filed 2018-02-27 | |||
| 2014-12-31 | $8.07M 10-K · filed 2017-02-23 | |||
| 2013-12-31 | $10.89M 10-K · filed 2016-02-19 | |||
| 2012-12-31 | $5.55M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |